Boundless Bio (NASDAQ: BOLD) posted a net loss of $12.9 million for the quarter ended December 31 2025, translating to earnings of –$0.58 per share. The loss beat the consensus estimate of –$1.16 per share, giving the company a $0.58‑per‑share beat that reflects disciplined cost management in a pre‑revenue stage.
The beat was driven largely by a reduction in research and development expenses, which fell to $9.8 million from $13.3 million in Q4 2024, and a modest decline in general and administrative costs to $4.2 million from $5.0 million. These lower operating outlays narrowed the quarterly loss despite the company’s continued investment in its lead oncology program.
Compared with the same period a year earlier, the Q4 2025 net loss of $12.9 million is an improvement over the $16.4 million loss reported in Q4 2024. Full‑year 2025 net loss of $58.2 million also improved from $65.4 million in 2024, and R&D and G&A expenses for the year were $44.8 million and $18.7 million, respectively, versus $55.3 million and $18.0 million a year earlier.
Boundless Bio reported $107.6 million in cash, cash equivalents and short‑term investments as of December 31 2025, a decline from $152.1 million a year earlier but sufficient to fund operations through the second half of 2028. The company reiterated that the cash reserve will support the next phase of its clinical development, including the ongoing KOMODO‑1 trial of its Kinesin degrader BBI‑940.
In a statement, President and CEO Zachary Hornby said, “With the KOMODO‑1 trial of BBI‑940 actively enrolling, we are excited to evaluate this potentially first‑in‑class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI‑940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof‑of‑concept readout within our existing cash runway.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.